Background/Objectives: A variety of dietary fibers have been shown to alter satiety hormone gene expression and secretion. The objective of this study was to examine plasma satiety hormone concentrations in healthy subjects consuming either PolyGlycopleX (PGX) or control (skim milk powder) for 21 days. Subjects/Methods: A randomized, double-blind, placebo-controlled clinical study was conducted in 54 healthy male and female adults. Participants consumed 5 g per day of PGX or control for 1 week followed by 2 additional weeks of 10 g per day of assigned product (n ¼ 27 per group). Primary outcomes measured at three visits (V1, V2 and V3) were plasma active glucagon-like peptide-1 (GLP-1) total ghrelin, peptide YY (PYY) and insulin.
Introduction
Numerous dietary fibers have been shown to regulate the secretion of gut satiety hormones (Reimer and McBurney, 1996; Cani et al., 2004; Adam and Westererp-Plantenga, 2005; Reimer and Russell, 2008) . Fermentable dietary fibers are more effective at promoting secretion of glucagon-like peptide-1 (GLP-1), one of many known anorexigenic peptides, than non-fermentable fibers (Reimer et al., 1997; Zhou et al., 2008) . In addition to fermentability, dietary fibers are also classified according to solubility. Some highly soluble dietary fibers (for example, inulin and oligofructose) are also fermented by gut microbiota in the colon and have been shown by Parnell and Reimer (2009) to alter the levels of peptide YY (PYY) and ghrelin in overweight and obese adults and by Cani et al. (2009) to increase levels of GLP-1 and PYY in normal weight adults. PYY, like GLP-1, reduces food intake while ghrelin, the only known peripheral orexigenic peptide, is associated with hunger (Wren and Bloom, 2007) . PolyGlycopleX (a-D-glucurono-a-D-manno-b-Dmanno-b-D-gluco), (a-L-gulurono-b-D-mannurono), b-D-glucob-D-mannan; (PGX); Inovobiologic Inc., Calgary, Canada) is a novel functional fiber complex manufactured by a proprietary process (EnviroSimplex) from three dietary fibers to form a highly viscous polysaccharide with high water holding and gel-forming properties (PGX, PolyGlycopleX and EnviroSimplex are registered trademarks of InovoBiologic Inc. All other trademarks belong to their respective owners.). A proprietary process causes strong interactions to form between konjac (glucomannan), sodium alginate and xanthan gum to produce a resultant polysaccharide complex with a level of viscosity that is higher than any currently known individual polysaccharide. The final product is a novel, soluble, highly viscous polysaccharide (functional fiber) that has been shown to be well tolerated by rodents (Matulka et al., 2009 ) and man (Carabin et al., 2009) . Genotoxicity studies of PGX have shown no mutagenic effects using bacterial reverse mutation and mouse micronucleus assays .
The previous clinical study by Carabin et al. (2009) evaluated tolerance to PGX for 21 days to a maximum dose of 10 g per day in healthy, normal weight male and female participants and concluded it was well tolerated with minimal adverse effects similar to those commonly observed with other dietary fibers. The objective of this study was to examine the levels of the gut satiety hormones, GLP-1, PYY and total ghrelin in these participants.
Materials and methods

Subjects
The randomized, double-blind, placebo-controlled trial evaluating PGX comprised a 2-week enrollment period followed by 3 weeks of PGX or placebo supplementation (Carabin et al., 2009) . Participants were healthy, nonsmoking, males and females, between the ages of 18 and 55 years with a body mass index (BMI) between 18.5 and 28.4 kg/m 2 .
Study design and products
Participants were randomly assigned to consume the test product (PGX; supplied by Inovobiologic Inc.; n ¼ 27) or control product (skimmed milk powder that was of similar color and texture; n ¼ 27) (Figure 1 ). Participants consumed 2.5 g of product twice a day as part of two main meals for the first 7 days, followed by 5 g twice a day for the last 14 days of the study. PGX and control product were pre-mixed with 10 g of a commercial breakfast cereal by CRID Pharma (Saint Gély du Fesc, France) and packaged with 135 ml of a commercially available plain yogurt. Participants combined the yogurt and pre-mixed product before ingestion. For the duration of the study, participants were instructed to abstain from consuming fiber-rich foods and limit dietary fiber intake to approximately 10 g per day. With the exception of the pre-mixed product and yogurt, all other food was purchased and prepared by the participants as per their usual diet.
Blood collection
Participants had assessments performed at four separate visits. Screening (visit 0, V0) took place over a 2-week period in which informed consent was obtained and a physical examination performed. A fasted blood sample was collected at the baseline visit (V1, day 0), the visit after 1 week of 5 g of product ingestion (V2, day 8±1), and the visit after 2 weeks of 10 g of product ingestion (V3, day 22±2). Blood collected at V1, V2 and V3 was used to determine satiety hormone levels. Blood was collected in an EDTA-treated tube with the addition of Diprotin A (0.034 mg/ml blood; MP Biomedicals, Illkirch, France) and centrifuged at 1500 Â g for 12 min at 4 1C. Plasma was stored at À80 1C until analysis.
Plasma analysis
Active GLP-1 was quantified using an enzyme-linked immunosorbent assay kit from LINCO Research (Millipore, St Charles, MO, USA). According to the manufacture, the assay sensitivity is 2 pM for a 100 ml sample size. The intraassay coefficient of variation (CV) is 8% and the inter-assay CV is 13% at 4 pM (Millipore). Total PYY and ghrelin were quantified using enzyme-linked immunosorbent assay kits from Phoenix Pharmaceuticals Inc. (Burlingame, CA, USA). The assay sensitivity for PYY was 0.06 and 0.13 ng/ml for ghrelin. Intra-assay CV was o5% for both assays and interassay CV o14% and o9% for PYY and ghrelin, respectively. Insulin was measured using an enzyme-linked immunosorbent assay kit from Millipore. The assay sensitivity is 2 mU/ml with an intra-assay CV o7% and inter-assay CV o11.4%.
Statistical analysis
Results are presented as mean±s.e.m. Peptide levels at the three visits were analyzed by repeated-measures analysis of variance with a Bonferroni adjustment (two-factor analysis with time (V1, V2 and V3) and diet as parameters). Associations between two variables were computed using Pearson correlation coefficients. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the formula (HOMA-IR ¼ fasting insulin (mU/ml) Â fasting glucose (mmol/l)/22.5). Data were analyzed using SPSS v 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
In total, 54 participants (25 males and 29 females) enrolled in and completed the study. No subjects withdrew from the study and the product was well tolerated as previously reported (Carabin et al., 2009 Body weight, glucose, insulin and HOMA-IR scores at V1, V2 and V3 are presented in Table 1 . There were no changes in body weight between V1 and V3 in the control and PGX groups (Table 1) . Fasting plasma glucose did not differ over time or between groups. Although there was a 14% reduction in fasting insulin between V1 and V3 with PGX, this difference was not significantly different from control. The mean raw and percent change scores between V1 and V3 for HOMA-IR were À0.04 or À3.6% for the control group and À0.21 or À18.3% in the PGX group. The percent decrease in HOMA-IR was significantly greater with PGX than control (P ¼ 0.03). Repeated-measures analysis of variance showed a P ¼ 0.067 for the effect of visit. When gender was included as a covariate in the repeated-measures analysis, the effect of visit was significant (P ¼ 0.024). When analyzed separately, males showed greater decreases in HOMA-IR scores than females (P ¼ 0.042) between V1 and V3. The reduction in HOMA-IR over time was similar for control and PGX in male participants (À0.36 ± 0.20 and À0.31 ± 0.18, respectively). In females, however, HOMA-IR scores were increased in the control group ( þ 0.18±0.17) and decreased in the PGX group (À0.08 ± 0.19).
There were no significant differences in fasting GLP-1 across visits or between groups (data not shown). Repeated-measures analysis showed a significant effect of visit (P ¼ 0.004) for fasting PYY levels (Figure 2) . When stratified by BMI those participants with BMIo23 kg/m 2 showed a significant effect of visit (P ¼ 0.03) and treatment (P ¼ 0.037). Analysis of variance showed a significantly higher level of PYY in the PGX group versus the control group at the end of the study (P ¼ 0.043). Repeated-measures analysis showed a significant effect of visit (Po0.001) for fasting total ghrelin levels ( Figure 3) . Reductions of 89.7±20.0 and 97.7±26.6 pmol/l were observed in the control and PGX groups, respectively, between V1 and V3.
PYY was negatively correlated with glucose at V2 (r ¼ À0.27, P ¼ 0.046). There were also significant negative correlations between ghrelin and insulin at V1 and V2 (r ¼ À0.28, P ¼ 0.038 and r ¼ À0.31, P ¼ 0.022 respectively) and between ghrelin and HOMA-IR at V1 and V2 (r ¼ À0.27, P ¼ 0.052 and r ¼ À0.28, P ¼ 0.041, respectively). Carabin et al. (2009) previously showed that 3 weeks of PGX supplementation is well tolerated by healthy subjects. In this study, we report that PGX is able to increase levels of fasting PYY compared with control product and this is statistically (Batterham et al., 2002) , and this impaired secretion may promote the development of obesity and/or hinder weight loss. Although the improvements in PYY levels in this study were observed in normal weight adults, the potential of PGX to enhance PYY levels in obese adults similar to other soluble fibers (Parnell and Reimer, 2009) 
Discussion
warrants investigation.
Although the participants in the control arm of our study saw a modest reduction in fasting PYY over the course of the 3-week study, the participants consuming PGX were able to maintain and in the case of those with BMIo23 kg/m 2 , increase their PYY levels. Cani et al. (2009) have recently shown that microbial fermentation of prebiotics is associated with an increase in GLP-1 and PYY production in healthy adults. In rodents, the by-products of microbial fermentation of dietary fiber, short chain fatty acids have been shown to directly stimulate PYY secretion (Dumoulin et al., 1998) . Konjac glucomannan, one of the primary fiber components of PGX, has been shown to increase fecal concentrations of acetate, propionate and butyrate in humans (Chen et al., 2008) . The viscosity of fibers has also independently been shown to affect food intake and this effect may be mediated by alterations in satiety hormone release. In a double-blind randomized, controlled and crossover trial, PGX preload significantly reduced ad libitum pizza intake in adolescents compared with two lower viscosity fibers (glucomannan and cellulose) (Vuksan et al., 2009 ).
The precise reason for the spontaneous reduction in PYY the control group and the maximum effect of PGX at 5 g is not entirely clear. All subjects were instructed to eat a low fiber diet consisting of approximately 10 g of fiber per day. In most cases, this level would represent a modest decrease in fiber intake for the participants to comply with the study protocol. As a high fiber diet has been shown to increase PYY levels (Cani et al., 2009; Parnell and Reimer, 2009) , it is possible that the reduction in fiber intake could spontaneously decrease PYY in the control subjects. The greatest effect of PGX on PYY was observed at the 5 g per day dose, which could be explained by an adaptive response. For example, the addition of 5 g per day of PGX fiber could trigger an acute heightened PYY response compared with placebo because of marked changes in the properties of the luminal contents because of the highly viscous nature of the product. When the dose was further increased to 10 g per day, the maximum effect may have already been achieved. It is possible that the maximum effect of the PGX was observed early on when the largest contrast was evident between the low fiber diet and the addition of the supplement. Meal-related PYY responses would be needed to fully interpret the changes we observed in the fasted state. (b) Fasting levels of PYY across V1, V2 and V3 for participants with a BMIo23 kg/m 2 (n ¼ 16 control, n ¼ 18 PGX). Repeated-measures ANOVA showed a significant effect of visit (P ¼ 0.03) and treatment (P ¼ 0.037). One-way ANOVA on V3 levels showed a significant effect of treatment (P ¼ 0.043). *A significant difference between control and PGX.
Additional studies investigating the temporal effects of PGX and adaptation to its physiological effects are warranted.
Levels of fasting ghrelin were suppressed in both the control and PGX groups between visits 1 and 3. As ghrelin stimulates food intake and promotes adiposity (Tschop et al., 2000; Wren et al., 2001) , compounds that attenuate the progressive rise in ghrelin before meals are attractive. Although the 8 pmol/l greater reduction in ghrelin observed in the PGX versus control group was not significantly different in our study, others have shown reductions in fasting and meal-related ghrelin with dietary fiber. Parnell and Reimer (2009) showed a significant reduction in ghrelin levels during a meal tolerance test in overweight and obese adults consuming 21 g per day of oligofructose for 3 months. In acute meal studies, Weickert et al. showed an effect of wheat fiber (Weickert et al., 2006b) but not oat fiber and no effect of cereal fiber (Weickert et al., 2006a) on ghrelin. Although the mechanisms by which dietary compounds suppress ghrelin are not well known, Overduin et al. (2005) suggested that the absorption rate of nutrients and the osmolarity of the intestinal lumen could have a role. PGX has a three-to fivefold greater viscosity than any currently known individual polysaccharide and is therefore likely to alter nutrient absorption along the intestine.
The reason for declining levels of ghrelin in both placebo and PGX groups is not completely clear. All subjects were instructed to follow a low fiber diet for the duration of the study. Although it is not expected that large changes were made to food choices by the subjects as a result of this recommendation, it is possible that some changes occurred in macronutrient intake. Carbohydrates, proteins and fats all suppress ghrelin secretion with varying potency; carbohydrate typically showing the greatest potency (Castaneda et al., 2010) . A positive correlation between dietary fiber intake and ghrelin has also been reported in overweight and obese postmenopausal women (St-Pierre et al., 2009 ). Higher intakes of dietary fiber were associated with higher levels of ghrelin, which the investigators interpreted as restoring ghrelin profiles to those observed in lean individuals. In our young, health cohort it is possible that consuming the low fiber diet for 3 weeks suppressed ghrelin secretion and the addition of PGX to the low fiber diet had little effect on further modifying fasting ghrelin levels.
We did not detect a difference in fasting GLP-1 levels between the two groups over the course of the 3 weeks. This lack of change in fasting levels of GLP-1 has been observed with ingestion of other dietary fibers (Juntunen et al., 2003; Adam and Westererp-Plantenga, 2005) . These same studies, however, do report significant increases in GLP-1 during a meal tolerance test and it is possible that PGX could cause similar nutrient-stimulated increases; this remains to be tested.
Although the concentrations of glucose and insulin in our healthy subjects were well within normal ranges, the 14% reduction in insulin over the course of the study in the PGX group and the 5.3-fold greater reduction in HOMA-IR scores with PGX versus control may be indicative of underlying improvements in insulin sensitivity. When expressed as a percent decrease, the reduction in HOMA-IR was significantly greater with PGX than control. A study specifically designed to address the role of PGX in modulating insulin resistance is warranted, and particularly in overweight subjects with impaired glucose tolerance.
The primary purpose of the clinical trial evaluating PGX was to assess gastrointestinal tolerance and any changes to hematological, biochemical, urinary and fecal parameters (Carabin et al., 2009 ). In addition, we now report that PGX increases fasting levels of PYY, a gut peptide involved in reducing food intake. Although our study was conducted with healthy participants and no changes in body weight were observed over the 3-week study, future studies specifically aimed at the effectiveness of PGX in overweight and insulin resistant populations is warranted.
